Applera Corporation
Applera Corporation is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Applera Corporation.
Applera Corporation is a company.
Key people at Applera Corporation.
Key people at Applera Corporation.
Applera Corporation was a major biotechnology company headquartered in Norwalk, Connecticut, focused on advancing life sciences through its two primary operating groups: Applied Biosystems and Celera Genomics.[1][2][3] The Applied Biosystems Group developed and marketed instrument-based systems, reagents, software, and services for analyzing nucleic acids (DNA/RNA), proteins, and small molecules, serving academic, biotech, pharmaceutical researchers, and commercial markets to enable scientific discoveries, drug development, and testing; it reported $1.4 billion in fiscal 2000 sales, growing to $1.6 billion in 2001 and $2.1 billion in fiscal 2007.[1][2][3][5] Celera Genomics provided genomic and medical information, evolving toward biopharmaceutical drug discovery and diagnostics, with a mission to leverage biology for improving the human condition.[1][2]
Applera symbolized the shift to genomics-driven innovation post-Human Genome Project, ranking #874 on the 2007 Fortune 1000 list as one of the largest U.S. biotech firms, though not publicly traded itself—instead using tracking stocks for its groups (ABI on NYSE).[2][3][4]
Applera traces its roots to Perkin-Elmer Corporation's Life Sciences Division. In 1981, Applied Biosystems Inc. was founded in Foster City, California; Perkin-Elmer merged with it in 1993, consolidating life science technologies into PE Biosystems by 1998, including Applied Biosystems, PerSeptive Biosystems, Tropix, and PE Informatics.[1][3] In 1999, to sharpen its life sciences focus, Perkin-Elmer recapitalized as PE Corp., sold its Analytical Instruments Division to EG&G for $425 million (ceding the Perkin-Elmer name), and rebranded to Applera Corporation, honoring the complementary roles of its groups.[1][3][4][5]
Tony L. White, chairman, president, and CEO, led this evolution, emphasizing Applera's role in providing tools and data for DNA/protein analysis amid the genomics boom.[1] Early traction came from Applied Biosystems' thermal cyclers and sequencers, pivotal for the Human Genome Project and new pharma development, with Life Sciences comprising 42% of Perkin-Elmer's $1+ billion 1994 revenues and 5,954 employees.[3][4]
Applera rode the late-1990s/early-2000s genomics revolution, fueled by the Human Genome Project, creating a competitive industry for pharma based on genetic insights.[1][3][4] Its timing was ideal: post-1999 recapitalization aligned with biotech's technology bubble, where Applied Biosystems' sequencers became essential for new genomics firms, influencing drug discovery acceleration.[3]
Market forces like rising demand for proteomics (post-gene sequencing) and personalized medicine favored Applera, positioning it as a key enabler in the "life science revolution" via tools for 42% of Perkin-Elmer's early revenues and sustained growth.[2][3] It shaped the ecosystem by supplying infrastructure for academic/clinical research, pharma manufacturing, and biotech startups, evolving from discovery tools to diagnostics/drug development.[2][5]
By 2008, Applera separated its Celera business and renamed to Applied Biosystems Inc., which merged with Invitrogen to form a combined entity targeting fall 2008 closure, amplifying its role in genetic/protein analysis amid maturing biotech markets.[5] Post-merger, the focus on innovative solutions for drug discovery and diagnostics persisted, building on Applera's legacy.
Trends like scaled bioinformatics for therapies and proteomics expansion would propel its influence, potentially evolving into broader precision medicine platforms—echoing its founding mission to harness biology's power for human advancement.[2] This trajectory underscores Applera's foundational impact, transforming from Perkin-Elmer's pivot into a biotech powerhouse.
